Pair page
Matrixyl with Syn-Ake
Mechanism-tag overlap and published literature for Matrixyl and Syn-Ake, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
collagen-signal-peptidecosmetic-peptide
cosmetic-snake-venom-mimetic
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Matrixyl and Syn-Ake have published these mechanism-level observations. Not a co-administration recommendation.
Signal peptide / matrikine claimed to upregulate dermal collagen, elastin, fibronectin, and glycosaminoglycan synthesis. Mechanism-distinct from Syn-Ake (matrix-building vs neuromuscular antagonism), so the two address different drivers of perceived skin aging — Matrixyl works on the dermal matrix to plump and firm, Syn-Ake on dynamic expression-wrinkle formation. Standard pairing in comprehensive anti-aging formulations.
Quick facts
Matrixyl
Syn-Ake
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2009 | Matrixyl | Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. PMID: 19570099. (UCSF Dermatology systematic review of topical peptides for aged skin, including Pal-KTTKS signal-peptide class.) PMID 19570099 | systematic review |
| 2010 | Matrixyl | Fu JJ, Hillebrand GG, Raleigh P, Li J, Marmor MJ, Bertucci V, Grimes PE, Mandy SH, Perez MI, Weinkle SH, Kaczvinsky JR. A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescri… PMID 20374604 | human trial |
| 2024 | Matrixyl | Vitali A, Paolicelli P, Bigi B, Trilli J, Di Muzio L, Carriero VC, Casadei MA, Petralito S. Liposome Encapsulation of the Palmitoyl-KTTKS Peptide: Structural and Functional Characterization. Pharmaceutics. 2024;16(2):219. PMID: 38399273. (Liposomal delivery system for Pal-KTTKS… PMID 38399273 | preclinical, in vitro |
| 2017 | Matrixyl | Park H, An E, Cho Lee AR. Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression. Tissue Eng Regen Med. 2017;14(1):73-80. PMID: 30603464. (CTGF / α-SMA modulation and fibrobl… PMID 30603464 | preclinical, in vitro |
| 2014 | Matrixyl | Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul). 2014;22(4):321-327. PMID: 25143811. (Demonstrates palmitoylation as stability and permeation enhancer relative to un… PMID 25143811 | preclinical, in vitro |
| 2013 | Matrixyl | Jones RR, Castelletto V, Connon CJ, Hamley IW. Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts. Mol Pharm. 2013;10(3):1063-1069. PMID: 23320752. (Direct fibroblast collagen-production dose-response for Pal-KTTKS linked to critical-aggregation-con… PMID 23320752 | preclinical, in vitro |
| 2019 | Matrixyl | Tałałaj U, Uscinowicz P, Bruzgo I, Surazynski A, Zareba I, Markowska A. The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity. Molecules. 2019;24(20):3698. PMID: 31618846. (Structure-activity series of KTTKS analogues with acetyl / lipoyl / pa… PMID 31618846 | mechanism / discovery |
| 2019 | Matrixyl | Mortazavi SM, Kobarfard F, Maibach HI, Moghimi HR. Effect of Palmitic Acid Conjugation on Physicochemical Properties of Peptide KTTKS: A Preformulation Study. J Cosmet Sci. 2019;70(6):299-312. PMID: 31829923. (Physicochemical characterization of palmitoyl conjugation effects on… PMID 31829923 | mechanism / discovery |
| 2007 | Matrixyl | Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. PMID: 18045359. (Updated Dermatologic Therapy review of signal, neurotransmitter-affecting, and carrier peptides.) PMID 18045359 | review |
| 2005 | Matrixyl | Osborne R, Mullins L, Jarrold B, Lintner K. In vitro skin structure benefits with a new antiaging peptide, Pal-KT. J Am Acad Dermatol. 2005;52(3 Suppl):P34. (AAD-meeting abstract on Pal-KT / Pal-KTTKS cosmetic evaluation; Procter & Gamble / Sederma collaboration.) | industry documentation |
| 2009 | Matrixyl | Trookman NS, Rizer RL, Ford R, Ho E, Gotz V. Immediate and Long-term Clinical Benefits of a Topical Treatment for Facial Lines and Wrinkles. J Clin Aesthet Dermatol. 2009;2(3):38-43. PMID: 20729942. (8-week topical treatment clinical study including palmitoyl pentapeptide active… PMID 20729942 | research article |
| 2005 | Matrixyl | Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. PMID: 18492182. (The 93-subject 12-week split-face vehicle-controlled RCT of 3 ppm Pa… PMID 18492182 | research article |
| 2012 | Syn-Ake | Beer K, Waibel J. Botulinum toxin type A enhances the duration of clinical effect of topically applied Acetyl Hexapeptide-8 in patients with blepharospasm. (Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of Blepharospasm in Patients Receiving Botulinum Neurotoxin Thera… | human pilot |
| 1995 | Syn-Ake | Tsai MC, Hsieh WH, Smith LA, Lee CY. Effects of waglerin-I on neuromuscular transmission of mouse nerve-muscle preparations. Toxicon. 1995;33(3):363-371. PMID: 7638875. PMID 7638875 | preclinical, in vivo |
| 1992 | Syn-Ake | Aiken SP, Sellin LC, Schmidt JJ, Weinstein SA, McArdle JJ. A novel peptide toxin from Trimeresurus wagleri acts pre- and post-synaptically to block transmission at the rat neuromuscular junction. Pharmacol Toxicol. 1992;70(6 Pt 1):459-462. PMID: 1359525. PMID 1359525 | preclinical, in vivo |
| 1991 | Syn-Ake | Weinstein SA, Schmidt JJ, Bernheimer AW, Smith LA. Characterization and amino acid sequences of two lethal peptides isolated from venom of Wagler's pit viper, Trimeresurus wagleri. Toxicon. 1991;29(2):227-236. PMID: 2048140. PMID 2048140 | mechanism / discovery |
| 2025 | Syn-Ake | Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. Cosmetics. 2025; PMC12193160. (Recent review of the most-studied class analog, evaluating skin permeation barriers — directly applicable to interpreting realistic Syn-Ake efficacy ceilings.) | review |
| 2022 | Syn-Ake | Anti-ageing peptides and proteins for topical applications: a review. Pharm Dev Technol. 2022;27(1):108-125. PMID: 34957891. (Recent comprehensive review of topical anti-aging peptides including discussion of nAChR-antagonist class members.) PMID 34957891 | review |
| — | Syn-Ake | Wikipedia / scholarly venomic summary: Tropidolaemus wagleri . Note: While T. wagleri 's waglerin-1 selectively blocks the ε-subunit-containing acetylcholine receptor of adult muscle, there is no scientific evidence supporting the manufacturer claim that the much smaller Syn-Ake… | industry documentation |
| 2002 | Syn-Ake | Molles BE, Tsigelny I, Nguyen PD, Gao SX, Sine SM, Taylor P. Residues in the epsilon subunit of the nicotinic acetylcholine receptor interact to confer selectivity of waglerin-1 for the alpha-epsilon subunit interface site. Biochemistry. 2002;41(25):7895-7906. PMID: 12069578. PMID 12069578 | research article |
| 2002 | Syn-Ake | Molles BE, Rezai P, Kline EF, McArdle JJ, Sine SM, Taylor P. Identification of residues at the alpha and epsilon subunit interfaces mediating species selectivity of Waglerin-1 for nicotinic acetylcholine receptors. J Biol Chem. 2002;277(7):5433-5440. PMID: 11724791. PMID 11724791 | research article |
| 2002 | Syn-Ake | Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. PMID: 18498523. (The pivotal cosmetic-peptide reference… PMID 18498523 | research article |
| 1999 | Syn-Ake | McArdle JJ, Lentz TL, Witzemann V, Schwarz H, Weinstein SA, Schmidt JJ. Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor. J Pharmacol Exp Ther. 1999;289(1):543-550. PMID: 10087048. (The pivotal paper establishing waglerin-1's selectiv… PMID 10087048 | research article |
| 1996 | Syn-Ake | Sellin LC, Mattila K, Annila A, Schmidt JJ, McArdle JJ, Hyvönen M, Rauh JJ, Kuusela P. Conformational analysis of a toxic peptide from Trimeresurus wagleri which blocks the nicotinic acetylcholine receptor. Biophys J. 1996;70(1):3-13. PMID: 8770182. PMID 8770182 | research article |
Related pair pages
More research context
Frequently asked
Have Matrixyl and Syn-Ake been studied together?
Researchers have published mechanistic-level co-administration discussion of Matrixyl and Syn-Ake. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Matrixyl and Syn-Ake share?
Matrixyl and Syn-Ake do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Matrixyl and Syn-Ake?
Matrixyl: Cosmetic ingredient (not a drug). Syn-Ake: Cosmetic ingredient (not drug-approved). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Matrixyl and Syn-Ake?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Matrixyl profile and the Syn-Ake profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026